{
    "references": [
        {
            "bibentry": "Champoux, JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001; 70: 369–413. PMID: 11395412",
            "process_entry": "True",
            "doi": "10.1146/annurev.biochem.70.1.369",
            "pmid": "11395412",
            "xmlid": "CIT0001"
        },
        {
            "bibentry": "Stewart, L, Redinbo, MR, Qiu, X, et al. A model for the mechanism of human topoisomerase I. Science 1998; 279: 1534–41. PMID: 9488652",
            "process_entry": "True",
            "doi": "10.1126/science.279.5356.1534",
            "pmid": "9488652",
            "xmlid": "CIT0002"
        },
        {
            "bibentry": "Berger, JM, Gamblin, SJ, Harrison, SC, et al. Structure and mechanism of DNA topoisomerase II. Nature 1996; 379: 225–32. PMID: 8538787",
            "process_entry": "True",
            "doi": "10.1038/379225a0",
            "pmid": "8538787",
            "xmlid": "CIT0003"
        },
        {
            "bibentry": "Pommier, Y, Sun, Y, Huang, SN, et al. Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. Nat Rev Mol Cell Biol 2016; 17: 703–21. PMID: 27649880",
            "process_entry": "True",
            "doi": "10.1038/nrm.2016.111",
            "pmid": "27649880",
            "xmlid": "CIT0004"
        },
        {
            "bibentry": "Szczesny, B, Brunyanszki, A, Ahmad, A, et al. Time-dependent and organ-specific changes in mitochondrial function, mitochondrial DNA integrity, oxidative stress and mononuclear cell infiltration in a mouse model of burn injury. PLoS One 2015; 10: e0143730. PMID: 26630679",
            "process_entry": "True",
            "doi": "10.1371/journal.pone.0143730",
            "pmid": "26630679",
            "pmcid": "PMC4668069",
            "xmlid": "CIT0005"
        },
        {
            "bibentry": "Pommier, Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev 2009; 109: 2894–902. PMID: 19476377",
            "process_entry": "True",
            "doi": "10.1021/cr900097c",
            "pmid": "19476377",
            "pmcid": "PMC2707511",
            "xmlid": "CIT0006"
        },
        {
            "bibentry": "Pommier, Y, Leo, E, Zhang, H, et al. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010; 17: 421–33. PMID: 20534341",
            "process_entry": "True",
            "doi": "10.1016/j.chembiol.2010.04.012",
            "pmid": "20534341",
            "xmlid": "CIT0007"
        },
        {
            "bibentry": "Ashour, ME, Atteya, R, El-Khamisy, SF. Topoisomerase-mediated chromosomal break repair: an emerging player in many games. Nat Rev Cancer 2015; 15: 137–51. PMID: 25693836",
            "process_entry": "True",
            "doi": "10.1038/nrc3892",
            "pmid": "25693836",
            "xmlid": "CIT0008"
        },
        {
            "bibentry": "Pommier, Y. Drugging topoisomerases: lessons and challenges. ACS Chem Biol 2013; 8: 82–95. PMID: 23259582",
            "process_entry": "True",
            "doi": "10.1021/cb300648v",
            "pmid": "23259582",
            "pmcid": "PMC3549721",
            "xmlid": "CIT0009"
        },
        {
            "bibentry": "Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006; 6: 789–802. PMID: 16990856",
            "process_entry": "True",
            "doi": "10.1038/nrc1977",
            "pmid": "16990856",
            "xmlid": "CIT0010"
        },
        {
            "bibentry": "Zhang, R, Li, Y, Cai, Q, et al. Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerase I. Cancer Chemoth Pharm 1998; 41: 257–67.",
            "process_entry": "True",
            "xmlid": "CIT0011"
        },
        {
            "bibentry": "Shao, J, Huang, F, Fu, J. Clinical study on treatment of non-small cell lung cancer with 10-hydroxycamptothecin. Chin J Clin Oncol 2003; 30: 26–8.",
            "process_entry": "True",
            "xmlid": "CIT0012"
        },
        {
            "bibentry": "Wu, N, Wu, XW, Agama, K, et al. A novel DNA topoisomerase I inhibitor with different mechanism from camptothecin induces G2/M phase cell cycle arrest to K562 cells. Biochemistry 2010; 49: 10131–6. PMID: 21033700",
            "process_entry": "True",
            "doi": "10.1021/bi1009419",
            "pmid": "21033700",
            "pmcid": "PMC3010555",
            "xmlid": "CIT0013"
        },
        {
            "bibentry": "Ganguly, A, Das, B, Roy, A, et al. Betulinic acid, a catalytic inhibitor of topoisomerase I, inhibits reactive oxygen species-mediated apoptotic topoisomerase I-DNA cleavable complex formation in prostate cancer cells but does not affect the process of cell death. Cancer Res 2007; 67: 11848–58. PMID: 18089815",
            "process_entry": "True",
            "doi": "10.1158/0008-5472.can-07-1615",
            "pmid": "18089815",
            "xmlid": "CIT0014"
        },
        {
            "bibentry": "Yu, LM, Zhang, XR, Li, XB, et al. Synthesis and biological evaluation of 6-substituted indolizinoquinolinediones as catalytic DNA topoisomerase I inhibitors. Eur J Med Chem 2015; 101: 525–33. PMID: 26188908",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2015.07.007",
            "pmid": "26188908",
            "pmcid": "PMC4558194",
            "xmlid": "CIT0015"
        },
        {
            "bibentry": "Qin, XJ, Yu, Q, Yan, H, et al. Meroterpenoids with antitumor activities from guava (Psidium guajava). J Agric Food Chem 2017; 65: 4993–9. PMID: 28578580",
            "process_entry": "True",
            "doi": "10.1021/acs.jafc.7b01762",
            "pmid": "28578580",
            "xmlid": "CIT0016"
        },
        {
            "bibentry": "Lian, Q, Xu, J, Yan, S, et al. Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation. Cell Res 2017; 27: 784–800. PMID: 28409562",
            "process_entry": "True",
            "doi": "10.1038/cr.2017.54",
            "pmid": "28409562",
            "pmcid": "PMC5518874",
            "xmlid": "CIT0017"
        },
        {
            "bibentry": "Syrovets, T, Büchele, B, Gedig, E, et al. Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIa. Mol Pharmacol 2000; 58: 71–81. PMID: 10860928",
            "process_entry": "True",
            "doi": "10.1124/mol.58.1.71",
            "pmid": "10860928",
            "xmlid": "CIT0018"
        },
        {
            "bibentry": "Castelli, S, Vieira, S, D, Annessa, I, Katkar, P, et al. A derivative of the natural compound kakuol affects DNA relaxationof topoisomerase IB inhibiting the cleavage reaction. Arch Biochem Biophys 2013; 530: 7–12. PMID: 23262316",
            "process_entry": "True",
            "doi": "10.1016/j.abb.2012.12.013",
            "pmid": "23262316",
            "xmlid": "CIT0019"
        },
        {
            "bibentry": "De Camargo, MS, Da Sliva, MM, Correa, RS, et al. Inhibition of human DNA topoisomerase IB by nonmutagenic ruthenium(II)-based compounds with antitumoral activity. Metallomics 2016; 8: 179–92. PMID: 26758075",
            "process_entry": "True",
            "doi": "10.1039/c5mt00227c",
            "pmid": "26758075",
            "xmlid": "CIT0020"
        },
        {
            "bibentry": "Takarada, JE, Guedes, APM, Correa, RS, et al. Ru/Fe bimetallic complexes: synthesis, characterization, cytotoxicity and study of their interactions with DNA/HSA and human topoisomerase IB. Arch Biochem Biophys 2017; 636: 28–41. PMID: 29107586",
            "process_entry": "True",
            "doi": "10.1016/j.abb.2017.10.015",
            "pmid": "29107586",
            "xmlid": "CIT0021"
        },
        {
            "bibentry": "Cheng, Y, An, LK, Wu, N, et al. Synthesis, cytotoxic activities and structure-activity relationships of topoisomerase I inhibitors: indolizinoquinoline-5,12-dione derivatives. Bioorg Med Chem 2008; 16: 4617–25. PMID: 18296054",
            "process_entry": "True",
            "doi": "10.1016/j.bmc.2008.02.036",
            "pmid": "18296054",
            "xmlid": "CIT0022"
        },
        {
            "bibentry": "Shoemaker, RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006; 6: 813–23. PMID: 16990858",
            "process_entry": "True",
            "doi": "10.1038/nrc1951",
            "pmid": "16990858",
            "xmlid": "CIT0023"
        },
        {
            "bibentry": "Holbeck, SL, Collins, JM, Doroshow, JH. Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol Cancer Ther 2010; 9: 1451–60. PMID: 20442306",
            "process_entry": "True",
            "doi": "10.1158/1535-7163.MCT-10-0106",
            "pmid": "20442306",
            "pmcid": "PMC2868078",
            "xmlid": "CIT0024"
        },
        {
            "bibentry": "Reinhold, WC, Sunshine, M, Varma, S, et al. Using CellMiner 1.6 for systems pharmacology and genomic analysis of the NCI-60. Clin Cancer Res 2015; 21: 3841–52. PMID: 26048278",
            "process_entry": "True",
            "doi": "10.1158/1078-0432.CCR-15-0335",
            "pmid": "26048278",
            "pmcid": "PMC4558215",
            "xmlid": "CIT0025"
        },
        {
            "bibentry": "Miao, ZH, Player, A, Shankavaram, U, et al. Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res 2007; 67: 8752–61. PMID: 17875716",
            "process_entry": "True",
            "doi": "10.1158/0008-5472.can-06-4554",
            "pmid": "17875716",
            "xmlid": "CIT0026"
        },
        {
            "bibentry": "Hsiang, YH, Hertzberg, R, Hecht, S, et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873–8. PMID: 2997227",
            "process_entry": "True",
            "pmid": "2997227",
            "xmlid": "CIT0027"
        },
        {
            "bibentry": "Urasaki, Y, Laco, GS, Pourquier, P, et al. Characterization of a novel topoisomerase I mutation from a camptothecin resistant human prostate cancer cell line. Cancer Res 2001; 61: 1964–9. PMID: 11280753",
            "process_entry": "True",
            "pmid": "11280753",
            "xmlid": "CIT0028"
        },
        {
            "bibentry": "Staker, BL, Hjerrild, K, Feese, MD, et al. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci USA 2002; 99: 15387–92. PMID: 12426403",
            "process_entry": "True",
            "doi": "10.1073/pnas.242259599",
            "pmid": "12426403",
            "pmcid": "PMC137726",
            "xmlid": "CIT0029"
        },
        {
            "bibentry": "Staker, BL, Feese, MD, Cushman, M, et al. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem 2005; 48: 2336–45. PMID: 15801827",
            "process_entry": "True",
            "doi": "10.1021/jm049146p",
            "pmid": "15801827",
            "xmlid": "CIT0030"
        },
        {
            "bibentry": "Wu, CP, Hsieh, CH, Wu, YS. The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy. Mol Pharm 2011; 8: 1996–2011. PMID: 21770407",
            "process_entry": "True",
            "doi": "10.1021/mp200261n",
            "pmid": "21770407",
            "xmlid": "CIT0031"
        },
        {
            "bibentry": "Zhu, J, Wang, R, Lou, L, et al. Jatrophane diterpenoids as modulators of P-glycoprotein-dependent multidrug resistance (MDR): advances of structure-activity relationships and discovery of promising MDR reversal agents. J Med Chem 2016; 59: 6353–69. PMID: 27328029",
            "process_entry": "True",
            "doi": "10.1021/acs.jmedchem.6b00605",
            "pmid": "27328029",
            "xmlid": "CIT0032"
        }
    ],
    "localid": "MED-30907213",
    "doi": "10.1080/14756366.2018.1516651",
    "pmid": "10.1080/14756366.2018.1516651",
    "pmcid": "30907213",
    "curator": "BEE EuropeanPubMedCentralProcessor",
    "source_provider": "Europe PubMed Central",
    "source": "https://www.ebi.ac.uk/europepmc/webservices/rest/30907213/fullTextXML",
    "reference_pointers": [
        [
            {
                "n_rp": 4,
                "xref_id": "CIT0001",
                "rp_string": "1–4",
                "pl_string": "1–4",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1,189)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 1,
                "xref_id": "",
                "pl_string": "1–4",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1,189)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 2,
                "xref_id": "",
                "pl_string": "1–4",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1,189)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 3,
                "xref_id": "",
                "pl_string": "1–4",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1,189)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 4,
                "xref_id": "CIT0001",
                "rp_string": "1–4",
                "pl_string": "1–4",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1,189)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 5,
                "xref_id": "CIT0002",
                "rp_string": "2",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),191,246)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 6,
                "xref_id": "CIT0005",
                "rp_string": "5",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),191,246)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 10,
                "xref_id": "CIT0006",
                "rp_string": "6–8",
                "pl_string": "6–8",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[4]",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),438,156)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 8,
                "xref_id": "",
                "pl_string": "6–8",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),438,156)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 9,
                "xref_id": "",
                "pl_string": "6–8",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),438,156)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 10,
                "xref_id": "CIT0006",
                "rp_string": "6–8",
                "pl_string": "6–8",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[4]",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),438,156)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 11,
                "xref_id": "CIT0007",
                "rp_string": "7",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),135,124)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 12,
                "xref_id": "CIT0009",
                "rp_string": "9",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),135,124)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 13,
                "xref_id": "CIT0010",
                "rp_string": "10",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),135,124)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 14,
                "xref_id": "CIT0007",
                "rp_string": "7",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),340,214)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "TOP1 inhibitors are grouped into two types as TOP1 “poisons” and “catalytic inhibitors” based on their molecular mechanism of action. TOP1 poisons are able to trap TOP1cc to prevent further religation and thus leading to irreversible DNA strand breaks7,9,10. Camptothecin (CPT) and many of its derivatives are the well-known TOP1 poisons. At present, four CPT derivatives have been approved for clinical treatment of tumor, including topotecan and irinotecan approved by FDA7,10, belotecan (in South Korea) and 10-hydroxy camptothecin (in China)7,11,12. Unlike poisons, TOP1 catalytic inhibitors act at the upstream stage of the catalytic DNA cleavage reaction of enzymes, and prevent the formation of TOP1cc13–16.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 15,
                "xref_id": "CIT0010",
                "rp_string": "10",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),340,214)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "TOP1 inhibitors are grouped into two types as TOP1 “poisons” and “catalytic inhibitors” based on their molecular mechanism of action. TOP1 poisons are able to trap TOP1cc to prevent further religation and thus leading to irreversible DNA strand breaks7,9,10. Camptothecin (CPT) and many of its derivatives are the well-known TOP1 poisons. At present, four CPT derivatives have been approved for clinical treatment of tumor, including topotecan and irinotecan approved by FDA7,10, belotecan (in South Korea) and 10-hydroxy camptothecin (in China)7,11,12. Unlike poisons, TOP1 catalytic inhibitors act at the upstream stage of the catalytic DNA cleavage reaction of enzymes, and prevent the formation of TOP1cc13–16.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 16,
                "xref_id": "CIT0007",
                "rp_string": "7",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),340,214)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "TOP1 inhibitors are grouped into two types as TOP1 “poisons” and “catalytic inhibitors” based on their molecular mechanism of action. TOP1 poisons are able to trap TOP1cc to prevent further religation and thus leading to irreversible DNA strand breaks7,9,10. Camptothecin (CPT) and many of its derivatives are the well-known TOP1 poisons. At present, four CPT derivatives have been approved for clinical treatment of tumor, including topotecan and irinotecan approved by FDA7,10, belotecan (in South Korea) and 10-hydroxy camptothecin (in China)7,11,12. Unlike poisons, TOP1 catalytic inhibitors act at the upstream stage of the catalytic DNA cleavage reaction of enzymes, and prevent the formation of TOP1cc13–16.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            }
        ],
        [
            {
                "n_rp": 17,
                "xref_id": "CIT0011",
                "rp_string": "11",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[7]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),340,214)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 18,
                "xref_id": "CIT0012",
                "rp_string": "12",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[8]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),340,214)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 23,
                "xref_id": "CIT0013",
                "rp_string": "13–16",
                "pl_string": "13–16",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),555,160)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 20,
                "xref_id": "",
                "pl_string": "13–16",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),555,160)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 21,
                "xref_id": "",
                "pl_string": "13–16",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),555,160)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 22,
                "xref_id": "",
                "pl_string": "13–16",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),555,160)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 23,
                "xref_id": "CIT0013",
                "rp_string": "13–16",
                "pl_string": "13–16",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),555,160)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 24,
                "xref_id": "CIT0017",
                "rp_string": "17",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,276)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "In spite of their effectiveness in solid tumors, CPT poisons suffer from many shortcomings, including bone marrow dose-limiting toxicity, severe gastrointestinal toxicity17, poor solubility, chemically instability under physiological pH, and drug efflux-mediated resistance10. Therefore, many investigations have focused on the discoveries of non-CPT poisons and the catalytic inhibitors13,14,18–21. In our previous study, the indolizinoquinolinedione derivatives have been discovered as a new class of TOP1 catalytic inhibitors13,15,22, which can inhibit TOP1 catalytic cleavage reaction, and prevent the formation of TOP1cc13. Further structural modification led to the discovery of several TOP1 catalytic inhibitors, among which CYB-L10 (Figure 1) showed good cytotoxicity and higher TOP1 inhibition than CPT without TOP1-mediated unwinding effect15. Therefore, it is worthy to systematically study its antitumor activity. Herein, we report the activity of CYB-L10 in vitro against 60 clinical cancer cell lines and in vivo in HCT116 xenograft mice model.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 25,
                "xref_id": "CIT0010",
                "rp_string": "10",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,276)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "In spite of their effectiveness in solid tumors, CPT poisons suffer from many shortcomings, including bone marrow dose-limiting toxicity, severe gastrointestinal toxicity17, poor solubility, chemically instability under physiological pH, and drug efflux-mediated resistance10. Therefore, many investigations have focused on the discoveries of non-CPT poisons and the catalytic inhibitors13,14,18–21. In our previous study, the indolizinoquinolinedione derivatives have been discovered as a new class of TOP1 catalytic inhibitors13,15,22, which can inhibit TOP1 catalytic cleavage reaction, and prevent the formation of TOP1cc13. Further structural modification led to the discovery of several TOP1 catalytic inhibitors, among which CYB-L10 (Figure 1) showed good cytotoxicity and higher TOP1 inhibition than CPT without TOP1-mediated unwinding effect15. Therefore, it is worthy to systematically study its antitumor activity. Herein, we report the activity of CYB-L10 in vitro against 60 clinical cancer cell lines and in vivo in HCT116 xenograft mice model.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            }
        ],
        [
            {
                "n_rp": 26,
                "xref_id": "CIT0013",
                "rp_string": "13",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),278,122)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 27,
                "xref_id": "CIT0014",
                "rp_string": "14",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),278,122)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 32,
                "xref_id": "CIT0018",
                "rp_string": "18–21",
                "pl_string": "18–21",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[5]",
                "pl_xpath": "/article/body/sec[1]/p[3]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),278,122)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 29,
                "xref_id": "",
                "pl_string": "18–21",
                "pl_xpath": "/article/body/sec[1]/p[3]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),278,122)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 30,
                "xref_id": "",
                "pl_string": "18–21",
                "pl_xpath": "/article/body/sec[1]/p[3]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),278,122)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 31,
                "xref_id": "",
                "pl_string": "18–21",
                "pl_xpath": "/article/body/sec[1]/p[3]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),278,122)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 32,
                "xref_id": "CIT0018",
                "rp_string": "18–21",
                "pl_string": "18–21",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[5]",
                "pl_xpath": "/article/body/sec[1]/p[3]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),278,122)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 33,
                "xref_id": "CIT0013",
                "rp_string": "13",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),401,228)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "In spite of their effectiveness in solid tumors, CPT poisons suffer from many shortcomings, including bone marrow dose-limiting toxicity, severe gastrointestinal toxicity17, poor solubility, chemically instability under physiological pH, and drug efflux-mediated resistance10. Therefore, many investigations have focused on the discoveries of non-CPT poisons and the catalytic inhibitors13,14,18–21. In our previous study, the indolizinoquinolinedione derivatives have been discovered as a new class of TOP1 catalytic inhibitors13,15,22, which can inhibit TOP1 catalytic cleavage reaction, and prevent the formation of TOP1cc13. Further structural modification led to the discovery of several TOP1 catalytic inhibitors, among which CYB-L10 (Figure 1) showed good cytotoxicity and higher TOP1 inhibition than CPT without TOP1-mediated unwinding effect15. Therefore, it is worthy to systematically study its antitumor activity. Herein, we report the activity of CYB-L10 in vitro against 60 clinical cancer cell lines and in vivo in HCT116 xenograft mice model.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 34,
                "xref_id": "CIT0015",
                "rp_string": "15",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[7]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),401,228)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "In spite of their effectiveness in solid tumors, CPT poisons suffer from many shortcomings, including bone marrow dose-limiting toxicity, severe gastrointestinal toxicity17, poor solubility, chemically instability under physiological pH, and drug efflux-mediated resistance10. Therefore, many investigations have focused on the discoveries of non-CPT poisons and the catalytic inhibitors13,14,18–21. In our previous study, the indolizinoquinolinedione derivatives have been discovered as a new class of TOP1 catalytic inhibitors13,15,22, which can inhibit TOP1 catalytic cleavage reaction, and prevent the formation of TOP1cc13. Further structural modification led to the discovery of several TOP1 catalytic inhibitors, among which CYB-L10 (Figure 1) showed good cytotoxicity and higher TOP1 inhibition than CPT without TOP1-mediated unwinding effect15. Therefore, it is worthy to systematically study its antitumor activity. Herein, we report the activity of CYB-L10 in vitro against 60 clinical cancer cell lines and in vivo in HCT116 xenograft mice model.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 35,
                "xref_id": "CIT0022",
                "rp_string": "22",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[8]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),401,228)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "In spite of their effectiveness in solid tumors, CPT poisons suffer from many shortcomings, including bone marrow dose-limiting toxicity, severe gastrointestinal toxicity17, poor solubility, chemically instability under physiological pH, and drug efflux-mediated resistance10. Therefore, many investigations have focused on the discoveries of non-CPT poisons and the catalytic inhibitors13,14,18–21. In our previous study, the indolizinoquinolinedione derivatives have been discovered as a new class of TOP1 catalytic inhibitors13,15,22, which can inhibit TOP1 catalytic cleavage reaction, and prevent the formation of TOP1cc13. Further structural modification led to the discovery of several TOP1 catalytic inhibitors, among which CYB-L10 (Figure 1) showed good cytotoxicity and higher TOP1 inhibition than CPT without TOP1-mediated unwinding effect15. Therefore, it is worthy to systematically study its antitumor activity. Herein, we report the activity of CYB-L10 in vitro against 60 clinical cancer cell lines and in vivo in HCT116 xenograft mice model.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 36,
                "xref_id": "CIT0013",
                "rp_string": "13",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),401,228)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "In spite of their effectiveness in solid tumors, CPT poisons suffer from many shortcomings, including bone marrow dose-limiting toxicity, severe gastrointestinal toxicity17, poor solubility, chemically instability under physiological pH, and drug efflux-mediated resistance10. Therefore, many investigations have focused on the discoveries of non-CPT poisons and the catalytic inhibitors13,14,18–21. In our previous study, the indolizinoquinolinedione derivatives have been discovered as a new class of TOP1 catalytic inhibitors13,15,22, which can inhibit TOP1 catalytic cleavage reaction, and prevent the formation of TOP1cc13. Further structural modification led to the discovery of several TOP1 catalytic inhibitors, among which CYB-L10 (Figure 1) showed good cytotoxicity and higher TOP1 inhibition than CPT without TOP1-mediated unwinding effect15. Therefore, it is worthy to systematically study its antitumor activity. Herein, we report the activity of CYB-L10 in vitro against 60 clinical cancer cell lines and in vivo in HCT116 xenograft mice model.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            }
        ],
        [
            {
                "n_rp": 37,
                "xref_id": "CIT0015",
                "rp_string": "15",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[11]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),630,224)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 38,
                "xref_id": "CIT0015",
                "rp_string": "15",
                "rp_xpath": "/article/body/sec[2]/sec[1]/p/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[1]/p),427,108)",
                "containers_title": [
                    "Methods and materials",
                    "General experiments"
                ]
            }
        ],
        [
            {
                "n_rp": 39,
                "xref_id": "CIT0018",
                "rp_string": "18",
                "rp_xpath": "/article/body/sec[2]/sec[3]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[3]/p),1,346)",
                "containers_title": [
                    "Methods and materials",
                    "NCI60 assay"
                ]
            }
        ],
        [
            {
                "n_rp": 40,
                "xref_id": "CIT0023",
                "rp_string": "23",
                "rp_xpath": "/article/body/sec[2]/sec[3]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[3]/p),1,346)",
                "containers_title": [
                    "Methods and materials",
                    "NCI60 assay"
                ]
            }
        ],
        [
            {
                "n_rp": 41,
                "xref_id": "CIT0024",
                "rp_string": "24",
                "rp_xpath": "/article/body/sec[2]/sec[3]/p/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[3]/p),1,346)",
                "containers_title": [
                    "Methods and materials",
                    "NCI60 assay"
                ]
            }
        ],
        [
            {
                "n_rp": 42,
                "xref_id": "CIT0015",
                "rp_string": "15",
                "rp_xpath": "/article/body/sec[3]/sec[1]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[1]/p),1,141)",
                "containers_title": [
                    "Results and discussion",
                    "Cytotoxicity for NCI60 cell lines"
                ]
            }
        ],
        [
            {
                "n_rp": 46,
                "xref_id": "CIT0023",
                "rp_string": "23–25",
                "pl_string": "23–25",
                "rp_xpath": "/article/body/sec[3]/sec[1]/p/xref[3]",
                "pl_xpath": "/article/body/sec[3]/sec[1]/p/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[1]/p),143,194)",
                "containers_title": [
                    "Results and discussion",
                    "Cytotoxicity for NCI60 cell lines"
                ]
            },
            {
                "n_rp": 44,
                "xref_id": "",
                "pl_string": "23–25",
                "pl_xpath": "/article/body/sec[3]/sec[1]/p/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[1]/p),143,194)",
                "containers_title": [
                    "Results and discussion",
                    "Cytotoxicity for NCI60 cell lines"
                ]
            },
            {
                "n_rp": 45,
                "xref_id": "",
                "pl_string": "23–25",
                "pl_xpath": "/article/body/sec[3]/sec[1]/p/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[1]/p),143,194)",
                "containers_title": [
                    "Results and discussion",
                    "Cytotoxicity for NCI60 cell lines"
                ]
            }
        ],
        [
            {
                "n_rp": 46,
                "xref_id": "CIT0023",
                "rp_string": "23–25",
                "pl_string": "23–25",
                "rp_xpath": "/article/body/sec[3]/sec[1]/p/xref[3]",
                "pl_xpath": "/article/body/sec[3]/sec[1]/p/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[1]/p),143,194)",
                "containers_title": [
                    "Results and discussion",
                    "Cytotoxicity for NCI60 cell lines"
                ]
            }
        ],
        [
            {
                "n_rp": 47,
                "xref_id": "CIT0026",
                "rp_string": "26",
                "rp_xpath": "/article/body/sec[3]/sec[2]/p[1]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/p[1]),122,149)",
                "containers_title": [
                    "Results and discussion",
                    "Cytotoxicity of CYB-L10 in drug-resistant cell lines"
                ]
            }
        ],
        [
            {
                "n_rp": 48,
                "xref_id": "CIT0010",
                "rp_string": "10",
                "rp_xpath": "/article/body/sec[3]/sec[2]/p[1]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/p[1]),272,256)",
                "containers_title": [
                    "Results and discussion",
                    "Cytotoxicity of CYB-L10 in drug-resistant cell lines"
                ],
                "pl_xpath": "substring(string(/article/body/sec[3]/sec[2]/p[1]),418,5)",
                "pl_string": "t10,2"
            },
            {
                "n_rp": 49,
                "xref_id": "CIT0027",
                "rp_string": "27",
                "rp_xpath": "/article/body/sec[3]/sec[2]/p[1]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/p[1]),272,256)",
                "containers_title": [
                    "Results and discussion",
                    "Cytotoxicity of CYB-L10 in drug-resistant cell lines"
                ],
                "pl_xpath": "substring(string(/article/body/sec[3]/sec[2]/p[1]),418,5)",
                "pl_string": "t10,2"
            }
        ],
        [
            {
                "n_rp": 50,
                "xref_id": "CIT0028",
                "rp_string": "28",
                "rp_xpath": "/article/body/sec[3]/sec[2]/p[2]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/p[2]),1,114)",
                "containers_title": [
                    "Results and discussion",
                    "Cytotoxicity of CYB-L10 in drug-resistant cell lines"
                ]
            }
        ],
        [
            {
                "n_rp": 51,
                "xref_id": "CIT0029",
                "rp_string": "29",
                "rp_xpath": "/article/body/sec[3]/sec[2]/p[2]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/p[2]),116,202)",
                "containers_title": [
                    "Results and discussion",
                    "Cytotoxicity of CYB-L10 in drug-resistant cell lines"
                ]
            }
        ],
        [
            {
                "n_rp": 52,
                "xref_id": "CIT0030",
                "rp_string": "30",
                "rp_xpath": "/article/body/sec[3]/sec[2]/p[2]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/p[2]),116,202)",
                "containers_title": [
                    "Results and discussion",
                    "Cytotoxicity of CYB-L10 in drug-resistant cell lines"
                ]
            }
        ],
        [
            {
                "n_rp": 53,
                "xref_id": "CIT0031",
                "rp_string": "31",
                "rp_xpath": "/article/body/sec[3]/sec[2]/p[3]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/p[3]),1,108)",
                "containers_title": [
                    "Results and discussion",
                    "Cytotoxicity of CYB-L10 in drug-resistant cell lines"
                ]
            }
        ],
        [
            {
                "n_rp": 54,
                "xref_id": "CIT0032",
                "rp_string": "32",
                "rp_xpath": "/article/body/sec[3]/sec[2]/p[3]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/p[3]),110,225)",
                "containers_title": [
                    "Results and discussion",
                    "Cytotoxicity of CYB-L10 in drug-resistant cell lines"
                ]
            }
        ]
    ]
}